The second part of this special issue contains five more interesting articles that expand the boundary of our understanding and knowledge on pharmaceutical direct-to-consumer advertising (DTCA). It is interesting to see that DTCA is now a mature research topic in the United States with more than fifteen years of solid empirical evidence. However, this research might also be of great relevance in many other countries as they evaluate whether to allow DTCA in the near future.